Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Sep;37(9):1831–1834. doi: 10.1128/aac.37.9.1831

Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin.

M Akova 1, O Uzun 1, H E Akalin 1, M Hayran 1, S Unal 1, D Gür 1
PMCID: PMC188077  PMID: 8239591

Abstract

Quinolones have been reported to be active against Brucella species in vitro. In this prospective randomized study, the efficacy and safety of the combination of ofloxacin plus rifampin were compared with the efficacy and safety of doxycycline plus rifampin, both combinations administered for a 6-week period in treatment of brucellosis. Sixty-one patients were enrolled in the study, and 49 had blood or bone marrow cultures positive for Brucella melitensis. Thirty patients received 200 mg of doxycycline plus 600 mg of rifampin once daily, and 31 patients were treated with 400 mg of ofloxacin plus 600 mg of rifampin once daily for 6 weeks. Nine patients in each group had complications of the disease. There was one therapeutic failure in the ofloxacin-rifampin treatment group, and one patient from each group relapsed (3.3% of those in the doxycycline-rifampin treatment group versus 3.2% of those in the ofloxacin-rifampin treatment group). Gastric discomfort was the major side effect observed in 13 patients (43.3%) who received doxycycline plus rifampin, whereas only 2 patients (6.5%) treated with ofloxacin plus rifampin complained of gastric irritation. These results suggest that the combination of ofloxacin plus rifampin administered for 6 weeks is as effective as doxycycline plus rifampin given for the same period, regardless of the presence of complications of the disease.

Full text

PDF
1831

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acocella G., Bertrand A., Beytout J., Durrande J. B., Garcia Rodriguez J. A., Kosmidis J., Micoud M., Rey M., Rodriguez Zapata M., Roux J. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J Antimicrob Chemother. 1989 Mar;23(3):433–439. doi: 10.1093/jac/23.3.433. [DOI] [PubMed] [Google Scholar]
  2. Colmenero Castillo J. D., Hernandez Marquez S., Reguera Iglesias J. M., Cabrera Franquelo F., Rius Diaz F., Alonso A. Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis. Chemotherapy. 1989;35(2):146–152. doi: 10.1159/000238662. [DOI] [PubMed] [Google Scholar]
  3. Feiz J. M., Sabbaghian H., Sohrabi F. A comparative study of therapeutic agents used for treatment of acute brucellosis. Br J Clin Pract. 1973 Nov;27(11):410–413. [PubMed] [Google Scholar]
  4. García-Rodriguez J. A., García Sánchez J. E., Trujillano I. Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother. 1991 Apr;35(4):756–759. doi: 10.1128/aac.35.4.756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gobernado M., Cantón E., Santos M. In vitro activity of ciprofloxacin against Brucella melitensis. Eur J Clin Microbiol. 1984 Aug;3(4):371–371. doi: 10.1007/BF01977500. [DOI] [PubMed] [Google Scholar]
  6. Khan M. Y., Dizon M., Kiel F. W. Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis. Antimicrob Agents Chemother. 1989 Aug;33(8):1409–1410. doi: 10.1128/aac.33.8.1409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lang R., Raz R., Sacks T., Shapiro M. Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis. J Antimicrob Chemother. 1990 Dec;26(6):841–846. doi: 10.1093/jac/26.6.841. [DOI] [PubMed] [Google Scholar]
  8. Llorens-Terol J., Busquets R. M. Brucellosis treated with rifampicin. Arch Dis Child. 1980 Jun;55(6):486–488. doi: 10.1136/adc.55.6.486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. MAGILL G. B., KILLOUGH J. H. Oxytetracycline-streptomycin therapy in brucellosis due to Brucella melitensis. AMA Arch Intern Med. 1953 Feb;91(2):204–211. doi: 10.1001/archinte.1953.00240140064005. [DOI] [PubMed] [Google Scholar]
  10. RUIZ CASTANEDA M. Laboratory diagnosis of brucellosis in man. Bull World Health Organ. 1961;24:73–84. [PMC free article] [PubMed] [Google Scholar]
  11. Reller L. B., Stratton C. W. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. J Infect Dis. 1977 Aug;136(2):196–204. doi: 10.1093/infdis/136.2.196. [DOI] [PubMed] [Google Scholar]
  12. Rubinstein E., Lang R., Shasha B., Hagar B., Diamanstein L., Joseph G., Anderson M., Harrison K. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother. 1991 Sep;35(9):1925–1927. doi: 10.1128/aac.35.9.1925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. al-Sibai M. B., Halim M. A., el-Shaker M. M., Khan B. A., Qadri S. M. Efficacy of ciprofloxacin for treatment of Brucella melitensis infections. Antimicrob Agents Chemother. 1992 Jan;36(1):150–152. doi: 10.1128/aac.36.1.150. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES